CN102089307B - 作为激酶抑制剂的吡咯并吡啶 - Google Patents

作为激酶抑制剂的吡咯并吡啶 Download PDF

Info

Publication number
CN102089307B
CN102089307B CN200980127299.4A CN200980127299A CN102089307B CN 102089307 B CN102089307 B CN 102089307B CN 200980127299 A CN200980127299 A CN 200980127299A CN 102089307 B CN102089307 B CN 102089307B
Authority
CN
China
Prior art keywords
alkyl
hydrogen
phenyl
base
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980127299.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102089307A (zh
Inventor
伊万·勒休劳
詹姆斯·F·布莱克
英德拉尼·W·冈瓦达纳
彼得·J·莫尔
埃利·M·华莱士
王斌
马克·奇卡莱利
迈克尔·莱昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102089307(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority to CN201910068067.1A priority Critical patent/CN109942575A/zh
Priority to CN201510289964.7A priority patent/CN104926810B/zh
Publication of CN102089307A publication Critical patent/CN102089307A/zh
Application granted granted Critical
Publication of CN102089307B publication Critical patent/CN102089307B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980127299.4A 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶 Expired - Fee Related CN102089307B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910068067.1A CN109942575A (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN201510289964.7A CN104926810B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5292608P 2008-05-13 2008-05-13
US61/052,926 2008-05-13
PCT/US2009/043691 WO2009140320A1 (en) 2008-05-13 2009-05-13 Pyrrolopyridines as kinase inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910068067.1A Division CN109942575A (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN201510289964.7A Division CN104926810B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Publications (2)

Publication Number Publication Date
CN102089307A CN102089307A (zh) 2011-06-08
CN102089307B true CN102089307B (zh) 2015-07-01

Family

ID=40810786

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200980127299.4A Expired - Fee Related CN102089307B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN201510289964.7A Expired - Fee Related CN104926810B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN201910068067.1A Pending CN109942575A (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201510289964.7A Expired - Fee Related CN104926810B (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶
CN201910068067.1A Pending CN109942575A (zh) 2008-05-13 2009-05-13 作为激酶抑制剂的吡咯并吡啶

Country Status (30)

Country Link
US (6) US8178131B2 (enExample)
EP (2) EP2307409B1 (enExample)
JP (2) JP5703212B2 (enExample)
KR (2) KR101643426B1 (enExample)
CN (3) CN102089307B (enExample)
AR (1) AR071717A1 (enExample)
AU (1) AU2009246402B2 (enExample)
BR (1) BRPI0913580B8 (enExample)
CA (1) CA2724262C (enExample)
CL (1) CL2009001152A1 (enExample)
CO (1) CO6321244A2 (enExample)
CR (1) CR11803A (enExample)
CY (1) CY1116692T1 (enExample)
DK (1) DK2307409T3 (enExample)
ES (1) ES2552643T3 (enExample)
HK (1) HK1219950A1 (enExample)
HR (1) HRP20151018T1 (enExample)
HU (1) HUE026160T2 (enExample)
IL (1) IL209258A (enExample)
MX (1) MX2010012449A (enExample)
NZ (1) NZ589318A (enExample)
PH (1) PH12013501779B1 (enExample)
PL (1) PL2307409T3 (enExample)
PT (1) PT2307409E (enExample)
RS (1) RS54358B1 (enExample)
RU (1) RU2517194C2 (enExample)
SI (1) SI2307409T1 (enExample)
TW (2) TWI554512B (enExample)
UA (1) UA111933C2 (enExample)
WO (1) WO2009140320A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101959887B (zh) 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
EP2242757B1 (en) 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
JP2009256298A (ja) * 2008-03-26 2009-11-05 Sumitomo Chemical Co Ltd ピペリジン−３−イルカーバメート化合物の光学分割方法およびその中間体
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CN102612365B (zh) * 2009-04-11 2017-04-12 阵列生物制药公司 用于强化dna损伤剂的检查点激酶1抑制剂
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP5749341B2 (ja) 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
TW201304778A (zh) 2010-11-16 2013-02-01 Array Biopharma Inc 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合
UA111075C2 (uk) 2011-02-25 2016-03-25 Еррей Біофарма Інк. Триазолопіридинові сполуки як інгібітори кінази рім
US9187486B2 (en) 2011-04-29 2015-11-17 Amgen Inc. Bicyclic pyridazine compounds as Pim inhibitors
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
AU2013252514B2 (en) 2012-04-23 2017-07-20 Genentech, Inc. Intermediates and processes for preparing compounds
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
KR102325163B1 (ko) 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (en) * 2013-08-22 2015-02-26 Genentech, Inc. Intermediates and processes for preparing compounds
AU2014324873B2 (en) 2013-09-25 2018-11-08 Vertex Pharmaceuticals Incorporated A selective inhibitor of phosphatidylinositol 3-kinase-gamma
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
CN107708414B (zh) 2015-06-30 2022-02-25 首尔伟傲世有限公司 适用紫外线发光二极管的捕虫器
SG11201802927VA (en) * 2015-11-04 2018-05-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
CN108779116A (zh) * 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
KR102916887B1 (ko) 2016-06-10 2026-01-22 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
MA53095A (fr) 2018-07-03 2021-05-12 Ifm Due Inc Composés et compositions pour traiter des états pathologiques associés à une activité de sting
CN108912032A (zh) * 2018-08-13 2018-11-30 南通大学 一种（3s，4r）-4-甲基吡咯烷-3-基氨基甲醇叔丁酯盐酸盐的化学合成方法
CN109053526A (zh) * 2018-08-13 2018-12-21 南通大学 一种（3r，4s）-4-甲基吡咯烷-3-基氨基甲酸叔丁酯盐酸盐的化学合成方法
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
WO2020150417A2 (en) 2019-01-17 2020-07-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2021207335A1 (en) 2020-04-07 2021-10-14 Syndax Pharmaceuticals, Inc. Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022150585A1 (en) 2021-01-08 2022-07-14 Ifm Due, Inc. Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
CA3213074A1 (en) 2021-05-14 2022-11-17 Salvacion Cacatian Inhibitors of the menin-mll interaction
PY2269135A (es) 2021-08-10 2024-01-29 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
CN119798252A (zh) * 2023-10-09 2025-04-11 中国石油化工股份有限公司 一种制备n邻位-酰基取代的含氮杂环化合物及其缩胺合铁(ii)配合物的方法
WO2025260014A1 (en) * 2024-06-14 2025-12-18 Tenvie Therapeutics, Inc. Compounds, compositions, and methods
WO2025261366A1 (zh) * 2024-06-18 2025-12-26 南京正大天晴制药有限公司 一种五元并六元杂环化合物及用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503783A (ja) * 1993-10-14 1997-04-15 アボツト・ラボラトリーズ キノリジノン型化合物
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
WO2003028724A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US6797825B2 (en) * 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
EP1613625A1 (en) 2003-03-14 2006-01-11 AstraZeneca AB Novel fused triazolones and the uses thereof
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005103050A2 (en) * 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
US7745436B2 (en) * 2004-04-13 2010-06-29 Synta Pharmaceuticals Corporation Disalt inhibitors of IL-12 production
GB0409080D0 (en) 2004-04-23 2004-05-26 Biofocus Discovery Ltd Compounds which interact with protein kinases
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
WO2006106326A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
EP1932841B1 (en) * 2005-08-30 2014-01-01 Asahi Kasei Pharma Corporation Sulfonamide compound
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
CA2624882C (en) 2005-10-06 2014-05-20 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
DE102006005180A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Indazol-heteroaryl-derivate
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
EP2170886A1 (en) * 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
AR069198A1 (es) 2007-11-07 2010-01-06 Schering Corp Derivados de ribosil pirimidinas moduladores de quinasas de control chk1,y composiciones farmaceuticas que los comprenden utiles en el tratamiento del cancer.
CN101959887B (zh) * 2008-01-08 2013-07-31 阵列生物制药公司 作为激酶抑制剂的吡咯并吡啶
EP2242757B1 (en) * 2008-01-09 2012-08-01 Array Biopharma, Inc. Pyrazolopyridines as kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US8481557B2 (en) * 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
US20140221370A1 (en) 2010-07-09 2014-08-07 Array Biopharma Inc. Pyrrolopyridines as kinase inhibitors
TW201304778A (zh) 2010-11-16 2013-02-01 Array Biopharma Inc 檢查點激酶１抑制劑及ｗｅｅ１激酶抑制劑之組合

Also Published As

Publication number Publication date
US20150322061A1 (en) 2015-11-12
US20130045286A1 (en) 2013-02-21
AR071717A1 (es) 2010-07-07
HUE026160T2 (en) 2016-05-30
US20160368916A1 (en) 2016-12-22
BRPI0913580B1 (pt) 2020-03-10
US20110070317A1 (en) 2011-03-24
PH12013501779B1 (en) 2019-02-13
TWI554512B (zh) 2016-10-21
PL2307409T3 (pl) 2016-01-29
BRPI0913580A2 (pt) 2015-10-20
PT2307409E (pt) 2015-11-04
SI2307409T1 (sl) 2015-11-30
CN102089307A (zh) 2011-06-08
KR20140093266A (ko) 2014-07-25
US9365568B2 (en) 2016-06-14
CL2009001152A1 (es) 2009-10-16
US20140243520A1 (en) 2014-08-28
JP2015098482A (ja) 2015-05-28
US8981085B2 (en) 2015-03-17
CA2724262A1 (en) 2009-11-19
US20140100369A1 (en) 2014-04-10
ES2552643T3 (es) 2015-12-01
AU2009246402B2 (en) 2013-05-23
US8178131B2 (en) 2012-05-15
EP2990407B1 (en) 2019-10-16
NZ589318A (en) 2011-06-30
AU2009246402A1 (en) 2009-11-19
JP5703212B2 (ja) 2015-04-15
CN104926810A (zh) 2015-09-23
CN109942575A (zh) 2019-06-28
TW201529573A (zh) 2015-08-01
CA2724262C (en) 2017-08-15
UA111933C2 (uk) 2016-07-11
KR20110008102A (ko) 2011-01-25
CN104926810B (zh) 2019-02-19
MX2010012449A (es) 2011-05-25
CR11803A (es) 2011-02-11
PH12013501779A1 (en) 2014-08-27
TWI458727B (zh) 2014-11-01
RU2010150786A (ru) 2012-06-20
DK2307409T3 (en) 2015-09-21
EP2307409A1 (en) 2011-04-13
CO6321244A2 (es) 2011-09-20
CY1116692T1 (el) 2017-03-15
HRP20151018T1 (hr) 2015-10-23
TW201002707A (en) 2010-01-16
EP2990407A1 (en) 2016-03-02
WO2009140320A1 (en) 2009-11-19
EP2307409B1 (en) 2015-08-12
IL209258A (en) 2017-01-31
BRPI0913580B8 (pt) 2021-05-25
KR101643426B1 (ko) 2016-07-27
KR101657856B1 (ko) 2016-09-19
RS54358B1 (sr) 2016-04-28
JP2011520896A (ja) 2011-07-21
HK1219950A1 (en) 2017-04-21
RU2517194C2 (ru) 2014-05-27
US8758830B2 (en) 2014-06-24
IL209258A0 (en) 2011-01-31
US8545897B2 (en) 2013-10-01
US9969727B2 (en) 2018-05-15
HK1152035A1 (en) 2012-02-17

Similar Documents

Publication Publication Date Title
CA2724262C (en) Pyrrolopyridines as kinase inhibitors
ES2708998T3 (es) Carboxamidas primarias como inhibidores de btk
RS58632B1 (sr) Supstituisana jedinjenja dihidroizohinolinona
EP2242755A1 (en) Pyrrolopyridines as kinase inhibitors
AU2013218743B2 (en) Pyrrolopyridines as kinase inhibitors
HK1152035B (en) Pyrrolopyridines as kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150701